Orexo US Blog Contact EN About Us Key Therapeutic Areas Pharmaceuticals Digital Therapies Sustainability Investors Media OREXO ABOUT US HISTORY History – celebrating 25 years of R&D 1995 Orexo is founded with a vision to develop improved pharmaceuticals, fulfilling unmet patient needs. This is done by optimization of the properties of well-documented substances in combination with Orexo’s innovative drug delivery technologies. 2000 The company´s first own developed product Diabact® UBT, for diagnosing of the gastric ulcer bacterium Helicobacter pylori, is approved in its first market. More markets will follow and today Diabact® UBT is commercialized worldwide through different partners. 2003 New owners contribute with financing and several development projects are started. 2005 Orexo is listed on the Nasdaq Stockholm stock exchange. 2008 The own developed product Abstral®, for treatment of breakthrough cancer, is approved in its first market. More markets will follow and today the product is commercialized worldwide through different partners. 2009 Orexo´s own developed product for insomnia is approved and is today commercialized by Mylan on multiple markets. 2010 The company issues new shares and Novo A/S enter Orexo as the largest shareholder. With the investment from Novo A/S the Board of Directors reviews the strategy and creates a vision of establishing a commercial business in the US based on Orexo’s proprietary products. 2013 Orexo establishes a commercial subsidiary in the US and launches ZUBSOLV®, for treatment of Opioid Use Disorder, in September 2013. The launch takes place just ten weeks after the FDA approval. 2015 Orexo divests its subsidiary Kibion, which also includes the product Diabact® UBT. 2016 After three years in the US, Orexo sells ZUBSOLV® for more than SEK 480 million and more than SEK 1 000 million gross in total, thereby reaching the first full year in history with profitability. 2018 The company wins a multiyear patent battle against the generic company Teva/Actavis securing patent protection for ZUBSOLV® in the US until 2032. Shortly thereafter the company internalizes its sales force. 2019 Orexo enters a partnership with GAIA AG, a world leader within digital therapeutics, with the aim to develop a digital therapy for treatment of opioid use disorder worldwide. The partnership enlarges when Orexo acquires the US rights for vorvida®, a scientifically proven digital therapy for alcohol misuse including alcohol use disorder. 2020 The digital portfolio continues to grow with a therapy for treatment of depression, deprexis®, also developed by Orexo´s partner GAIA and with multiple clinical trials showing its efficacy. Orexo owns the US rights for deprexis®. ZUBSOLV® US gross sales since start reached USD 1 billion. Thanks and welcome back! ©2021 Orexo AB (publ.) – All rights reserved Contact | Dictionary & Definitions | Privacy Policy | Legal notice | Cookie policy